Passive serotherapy can confer immediate protection against microbial infection, but methods to rapidly generate human neutralizing monoclonal antibodies are not yet available. We have developed an improved method for Epstein-Barr virus transformation of human B cells. We used this method to analyze the memory repertoire of a patient who recovered from severe acute respiratory syndrome coronavirus (SARS-CoV) infection and to isolate monoclonal antibodies specific for different viral proteins, including 35 antibodies with in vitro neutralizing activity ranging from 10(-8)M to 10(-11)M. One such antibody confers protection in vivo in a mouse model of SARS-CoV infection. These results show that it is possible to interrogate the memory repertoi...
SARS-CoV-2 is the pathogen responsible for the COVID-19 pandemic, affecting more than 131 million in...
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic ...
A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with ...
Antibodies that neutralize SARS-CoV-2, are thought to provide the most immediate and effective treat...
We report the isolation of two human IgG1k monoclonal antibodies (mAbs) directed against the SARS-Co...
Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently n...
Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly develope...
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory infection and cont...
Abs that neutralize SARS-CoV-2 are thought to provide the most immediate and effective treatment for...
Patients who recover from SARS-CoV-2 infections produce antibodies and antigen-specific T cells agai...
Abstract Monoclonal antibodies that target SARS-CoV-2 with high affinity are valuable for a wide ran...
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce i...
AbstractPassive therapy with neutralizing human monoclonal antibodies (mAbs) could be an effective t...
Neutralising antibodies are an essential component in the immune response to virus infection and are...
The outbreaks of emerging infectious diseases caused by pathogens such as SARS coronavirus, H5N1, H1...
SARS-CoV-2 is the pathogen responsible for the COVID-19 pandemic, affecting more than 131 million in...
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic ...
A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with ...
Antibodies that neutralize SARS-CoV-2, are thought to provide the most immediate and effective treat...
We report the isolation of two human IgG1k monoclonal antibodies (mAbs) directed against the SARS-Co...
Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently n...
Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly develope...
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory infection and cont...
Abs that neutralize SARS-CoV-2 are thought to provide the most immediate and effective treatment for...
Patients who recover from SARS-CoV-2 infections produce antibodies and antigen-specific T cells agai...
Abstract Monoclonal antibodies that target SARS-CoV-2 with high affinity are valuable for a wide ran...
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce i...
AbstractPassive therapy with neutralizing human monoclonal antibodies (mAbs) could be an effective t...
Neutralising antibodies are an essential component in the immune response to virus infection and are...
The outbreaks of emerging infectious diseases caused by pathogens such as SARS coronavirus, H5N1, H1...
SARS-CoV-2 is the pathogen responsible for the COVID-19 pandemic, affecting more than 131 million in...
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic ...
A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with ...